Search
Close this search box.
Search
Close this search box.

Infographic

Confronting the life science diversity problem

Using technology to address issues of diversity and inclusion across the drug development lifecycle.

Only 32%

of organizations have outreach programs to encourage a more culturally/ethnically diverse workforce. – INFORMA CONNECT

Women’s representation remains low in clinical trials, particularly in phase I trials (≈22%). – BMJ

Improving diversity and inclusion in life science is more than just the right thing to do – there’s also a sound business imperative to do so.

Companies with above-average diversity produced a greater proportion of revenue from innovation (45% of total). – FORBES

In 2019, top-quartile companies [for ethnic diversity] outperformed those in the fourth quartile by 36% in profitability. – MCKINSEY

Diversity in clinical trial recruitment is a significant shortfall for life science companies, with a number of barriers to participation excluding underserved communities.

53% of non-Hispanic white participants said that they trusted their health professionals ‘a lot,’ compared with 37% for non-Hispanic black participants and 36% for Hispanic participants.”

Patients travel an average of 25.8 miles for clinical trial visits.

75% of participants in US clinical trials are white

– FDA

Technologies including artificial intelligence, network analytics, social listening, and virtual asynchronous engagement are helping to remove these barriers to trial participation.

An AI-enhanced trial at Cedars-Sinai identified 16 candidates in one hour, while a human-based approach found two people in six months.

– FORBES

“Decentralization broaden trial access to reach a larger number and potentially a more diverse pool of patients.”

– MCKINSEY

An AI-enhanced trial at Cedars-Sinai identified 16 candidates in one hour, while a human-based approach found two people in six months.

– FORBES

Expert identification is another area where life science falls short, with many companies continuing to rely on the same pool of established KOLs.

64% of members considered speaker diversity a necessity…

Network analytics can reveal the ‘invisible college’ within a disease community, based on true network influence rather than volume of activity.

Even when diversity has been achieved, hierarchy bias within the life science sector prevents all voices from being heard.

of female business leaders say it’s difficult for women to speak up in virtual meetings. 

CATALYST

By anonymizing participants through anonymous questions, asynchronous virtual engagement can ensure that every voice is heard – effectively eliminating hierarchy bias.

“Anonymous survey methods appear to promote greater disclosure of sensitive or stigmatizing information compared to non-anonymous methods.”

– NATIONAL LIBRARY OF MEDICINE

“Diverse groups who are visually anonymous will produce more creative results than homogeneous groups or groups who are diverse but not visually anonymous.”

– RESEARCHGATE

While technology isn’t a magic bullet, it can effectively support life science companies’ existing diversity and inclusion efforts to smooth the way for a more equitable, representative future. Discover the four technologies supporting life science D&I efforts in our e-book: Confronting the Life Science Diversity Problem.

More insights, direct to your inbox.